Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

- PMLiVE

Amgen boosts Japan prospects with Astellas partnership

Companies establish joint venture and plan to co-develop new medicines

- PMLiVE

Merck & Co drops Parkinson’s prospect preladenant

No better than placebo during phase III trial

- PMLiVE

Merck & Co inches closer to US green light for insomnia drug

FDA panel backs suvorexant, although some concerns about high dosages

- PMLiVE

Clinical trial regulation in Mexico

Regulatory improvements make Mexico an appealing destination for clinical trials outsourcing

- PMLiVE

Novartis wins third NICE recommendation for Lucentis

Gains final backing to treat NHS patients with macular oedema

UCB and IBM to harness big data for personalised epilepsy care

Joint project could pave the way for therapy area use of IBM's Watson

Amgen and Novartis partner with biotech venture capital firm

Atlas Venture fund aims to create 15 new biotech companies

- PMLiVE

NIHR streamlines clinical trials service for pharma

Aims to help speed up studies in the NHS in England

Novartis building

Novartis gets FDA green light for new Ilaris indication

Immunotherapeutic wins US approval for severe form of childhood arthritis

- PMLiVE

Amgen forms joint venture in China to boost Vectibix

Partners with Zhejiang Beta Pharma on colon cancer drug

- PMLiVE

FDA to review Merck & Co’s allergy immunotherapy

Accepts application for oral tablet to protect against ragweed-based allergies

- PMLiVE

Steve Arnold joins UCB from Gilead

Appointed managing director for the British and Irish Isles

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links